Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
The Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, indicating an active prosecution phase for the institute. Furthermore, the portfolio is being reviewed within 3 distinct art units, which suggests that the institute's research and patent applications cover several different specialized sub-fields within biotechnology.
BOESEN, AGNIESZKA is the busiest examiner for the institute, currently overseeing 2 pending office actions. This means that while the institute has 5 pending office actions in total, the busiest examiner is responsible for 2 of those actions. The remaining pending actions are spread among the other distinct examiners. This distribution across 3 distinct art units and 4 distinct examiners requires a coordinated strategy to manage the different perspectives and requirements of the various reviewers.
Practitioners should note that with 5 pending office actions and 4 distinct examiners, the institute faces a diverse set of challenges that may require varied technical and legal arguments to secure patent protection in the Biotechnology & Pharmaceuticals sector. Understanding the specific tendencies of BOESEN, AGNIESZKA will be important given her 2 pending office actions. This approach will help the institute navigate the complexities of the current examination process across 3 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, AGNIESZKA | 2 | 68.5% | +21.8% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 56d overdue |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 56d overdue |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 33d |
| 18259711 | HUMAN PAPILLOMAVIRUS TYPE 58 CHIMERIC PROTEIN AND USE THEREOF | BOESEN, AGNIESZKA | — |
| 18259538 | HUMAN PAPILLOMAVIRUS TYPE 18 CHIMERIC PROTEIN AND USE THEREOF | BOESEN, AGNIESZKA | — |
| Art Unit | Apps |
|---|---|
| 1672 | 3 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259711 | HUMAN PAPILLOMAVIRUS TYPE 58 CHIMERIC PROTEIN AND USE THEREOF | BOESEN, AGNIESZKA | 1672 | §112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18259538 | HUMAN PAPILLOMAVIRUS TYPE 18 CHIMERIC PROTEIN AND USE THEREOF | BOESEN, AGNIESZKA | 1672 | §112 | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §102§103 | Final Rejection | 33d | Pending | May 25, 2023 |
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 1618 | §102§112 | Final Rejection | 56d overdue | Pending | Jan 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial